Skip to main content

Pathways to lung cancer diagnosis among individuals who did not receive lung cancer screening: a qualitative study



Although early detection of lung cancer through screening is associated with better prognosis, most lung cancers are diagnosed among unscreened individuals. We therefore sought to characterize pathways to lung cancer diagnosis among unscreened individuals.


Participants were individuals with lung cancer who did not undergo asymptomatic lung cancer screening (n = 13) and healthcare providers who may be involved in the pathway to lung cancer diagnosis (n = 13). We conducted semi-structured interviews to identify themes in lung cancer patients’ narratives of their cancer diagnoses and providers’ personal and/or professional experiences of various pathways to lung cancer diagnoses, to identify delays in diagnosis. We audio-recorded, transcribed, and coded interviews in two stages. First, we conducted deductive coding using three time-period intervals from the Models of Pathways to Treatment framework: appraisal, help-seeking, and diagnostic (i.e., excluding pre-treatment). Second, we conducted inductive coding to identify themes within each time-period interval, and classified these themes as either barriers or facilitators to diagnosis. Coding and thematic summarization were completed independently by two separate analysts who discussed for consensus.


Eight of the patient participants had formerly smoked, and five had never smoked. We identified eight barrier/facilitator themes within the three time-period intervals. Within the appraisal interval, the barrier theme was (1) minimization or misattribution of symptoms, and the facilitator theme was (2) acknowledgment of symptoms. Within the help-seeking interval, the barrier theme was (3) hesitancy to seek care, and the facilitator theme was (4) routine care. Within the diagnosis interval, barrier themes were (5) health system challenges, and (6) social determinants of health; and facilitator themes were (7) severe symptoms and known risk factors, and (8) self-advocacy. Many themes were interrelated, including minimization or misattribution of symptoms and hesitancy to seek care, which may collectively contribute to care and imaging delays.


Interventions to reduce hesitancy to seek care may facilitate timely lung cancer diagnoses. More prompt referral to imaging—especially computed tomography (CT)—among symptomatic patients, along with patient self-advocacy for imaging, may reduce delays in diagnosis.

Peer Review reports


Lung cancer is the leading cause of cancer mortality in the United States (U.S.), and the second most commonly diagnosed cancer among men and women [1]. 46% of lung cancers are diagnosed at distant stage when five-year survival is 6%, while just 24% of cases are diagnosed at localized stage when five-year survival is 60% [1]. Routine screening can help detect cases at earlier stage, [2] but screening is only recommended for specific groups of non-symptomatic individuals at highest risk for lung cancer [3]. Since 2013, the United States Preventive Services Task Force (USPSTF) has recommended that eligible individuals receive annual screening through low-dose computed tomography (LDCT) [3,4,5]. Most lung cancer diagnoses occur in individuals who are not screened due to both the lack of eligibility among many based on age and/or smoking history, as well as low screening uptake among those who are eligible [6, 7].

Early-stage lung cancer is typically asymptomatic, presenting challenges to early diagnosis [8]. As lung cancer progresses, symptoms including cough, chest pain, shortness of breath, and weight loss [8, 9] can mimic other diseases (e.g., asthma) or causes (e.g., allergies), or develop in the presence of comorbidities such as chronic obstructive pulmonary disease [8]. In the U.S., patients with persistent or severe acute symptoms are typically referred for chest radiographs (X-rays) as opposed to computed tomography (CT) scans, especially in the absence of other known risk factors [10]. People who never smoked may face delays in obtaining a lung cancer diagnosis. Some studies suggest that limited knowledge of lung cancer symptoms, risk perception, and clinical bias could contribute to diagnosis delays in people who never smoked [11, 12]. Since the incidence rate of lung cancer in people who never smoked is 12 to 30 times lower than the incidence rate among people who currently smoke, [13] it makes sense for providers to have low suspicion of lung cancer upon initial presentation of symptoms in people who never smoked; however, providers should consider lung cancer in the differential diagnosis of symptomatic patients [14].

While some studies have examined patient experiences leading up to a lung cancer diagnosis, [15,16,17,18,19,20] few studies have examined pathways to lung cancer diagnosis from both patient and provider perspectives [21, 22]. Prior Australia-based studies identified barriers to lung cancer diagnosis including patient rural residence and limited knowledge among some primary care providers regarding how or where to refer patients to specialists, and facilitators including patient social network concern fueling a sense of urgency to seek care [21, 22]. A study in the United Kingdom found that the pathways to lung cancer diagnosis can vary beyond primary care-initiated routes, justifying a need for research to consider differential routes to diagnosis, such as emergency department admissions [23]. Pathways to lung cancer diagnosis may differ among U.S. patients, as primary care-seeking patterns differ from other countries. The specialties of primary care providers vary in the U.S.; for example, 20% of respondents in one survey of American women considered their obstetrician-gynecologist as their primary care provider [24]. Approximately 25% of American adults lack a primary care provider [25]. Past U.S.-based studies conducted among lung cancer patients identified various experiences and care-seeking behaviors prior to a lung cancer diagnosis including symptoms that the patient or their doctor attributed to other causes, and experiencing severe acute symptoms that lead to immediate care seeking, often at an emergency department [19, 26].

Pathways to diagnosis include all of the processes and experiences leading up to a diagnosis. The Model of Pathways to Treatment (MPT) is a framework that characterizes pathways to disease diagnosis and treatment within time intervals. The first three intervals encompass the time periods leading up to and including diagnosis: appraisal, help-seeking, and diagnostic (i.e., excluding pre-treatment) (Fig. 1) [27, 28]. The MPT framework has been used in prior studies of cancer and has helped to identify barriers and facilitators in the pathway to diagnosis [21, 22, 29,30,31,32]. In this study, we used the framework to identify themes leading up to a lung cancer diagnosis in a U.S. academic healthcare system. We examined the perspectives of both patients and providers to characterize pathways to lung cancer diagnosis among unscreened individuals to inform opportunities for intervention that could promote earlier detection of lung cancer.


Procedures and participants

This study and all procedures were approved by the Institutional Review Board (IRB) at the University of Utah (IRB #00123466). Lung cancer patients were eligible to participate in the study if they had not received asymptomatic screening, were English-speaking, received care at the University of Utah, and had consented to the Total Cancer Care Study, [33] which enrolls individuals who are diagnosed with any cancer type at the Huntsman Cancer Institute. Study staff identified eligible patients by chart review or physician referral. No patients were excluded based on age, gender, race, ethnicity, stage at diagnosis, or time since diagnosis. Eligible patients were invited to participate through e-mail and a subsequent phone call. We did not restrict based on patient smoking histories when inviting the first batch of participants. After the first batch, we used purposive sampling to preferentially invite those with no or < 30 pack-year smoking histories to target patients ineligible for asymptomatic screening according to the 2013 USPSTF recommendations. Of 35 patients contacted, two declined, 16 did not respond, three set up interviews but did not complete them, and 14 completed interviews. One of the interviewees was later excluded, as their tumor histologic type was identified as likely not lung cancer upon review, leaving a total of 13 completed interviews for analysis.

Providers were eligible to participate in the study if they were a practicing physician in the University of Utah health system. We did not exclude providers based on credentials or specialty in order to assess perspectives from a variety of providers who may be involved in the pathway to lung cancer diagnoses. Study staff identified eligible providers through the University of Utah “Find a Doctor” website or by referral. Eligible providers were invited to participate via e-mail. Of 112 providers contacted, eight declined, 91 did not respond, and 13 completed interviews.

Data collection

We conducted semi-structured interviews (by authors LG, female Ph.D.; KLM, female M.P.H.; MO, female medical student; and SG, female medical student) between October 18, 2019, and September 7, 2021. Interviews were conducted with patients by telephone and with providers either in-person or by telephone. All interviews began with an informed consent process, and participants were e-mailed a copy of the consent cover letter. Interviews did not have a time limit; interviews were a median of 21 min (range 11–71) with patients and a median of 23 min (range 17–53) with providers. All interviews were audio-recorded and transcribed after the interview using the Microsoft Office 365 transcribe tool, followed by review and corrections by study staff. Participants were not re-contacted post-interview and did not provide feedback on transcripts or findings.

Patient interviews focused on the events leading up to their lung cancer diagnosis, including symptoms, healthcare usage, medications for related symptoms and pre-existing conditions, and diagnostic tests using semi-structured interview questions previously published [34]. Patients were also asked open-ended questions, including, “Could you tell me about your cancer story?” and “What drove you to seek care initially?” Topics also included which types of providers were seen prior to diagnosis. Patient electronic health records were accessed to collect demographic information (sex, age at diagnosis, race, and ethnicity), smoking status, smoking pack-year history among people who ever smoked, cancer histologic subtype, stage at diagnosis, and diagnosis date. Patient characteristics are shown in Supplementary Table 1.

Provider interviews focused on the most common pathway to lung cancer diagnosis from symptoms, if existent, through diagnosis. Providers were asked to respond with respect to their personal or professional experiences, as some providers may have rarely or not knowingly participated in patient referral pathways that resulted in a lung cancer diagnosis. Question topics included presenting symptoms that providers associate with lung cancer, differences in diagnosis pathways between patients with and without a history of smoking, patient behaviors that raise or lower the index of suspicion for lung cancer, and what factors the provider thought may influence a patient’s pathway to diagnosis [34].

Data analysis

Data were analyzed using a two-phase thematic analysis framework following the applied thematic analysis approach [35]. In the initial deductive phase, the two analysts (authors LG and RDM) coded excerpts from interview transcripts using the appraisal, help-seeking, and diagnostic intervals. Using the MPT framework [27, 28] and the Aarhus statement [36] as frameworks, we defined the intervals using the definitions in Table 1. After each transcript was independently coded, the analysts met to discuss and reach consensus.

Table 1 Appraisal, help-seeking, and diagnostic interval defined beginning and end

Once the initial deductive coding phase was completed, the two analysts (authors LG and RDM) independently reviewed the code reports to identify broad themes in each of the first three time-period intervals. The analysts then met to discuss and reach consensus on the themes and to finalize the codebook (Supplementary Table 2). The two reviewers used the codebook to independently code the transcripts, and then met to compare codes and reach consensus. The two reviewers independently examined code reports to classify broad themes as barriers and facilitators to lung cancer diagnosis, then met to discuss and finalize the theme categorization. We summarized the final themes in tables and identified representative quotes. Quotes were lightly edited by removing filler words such as “um,” “like,” and “you know” for concision and clarity. All coding and analyses were conducted in Dedoose Version 9.0.46 [37].


Participant demographics

The majority of the 13 patient participants were female (n = 8, 62%) (Supplementary Table 1) and non-Hispanic White (n = 12, 92%). The median age at diagnosis was 66 years (range 44–81). The majority of patients had a history of smoking (n = 8, 62%). While four had smoking histories of < 30 pack years, another four had smoking histories of ≥ 30 pack years. At diagnosis, two resided in rural areas and the others in urban areas. The distribution of stage at diagnosis was: IIB (n = 2, 15%); IIIA (n = 3, 23%); IIIB (n = 1, 8%); and IV (n = 7, 54%). The majority of patients were diagnosed with adenocarcinoma (n = 9, 69%). Other histotypes included large cell neuroendocrine carcinoma, neuroendocrine carcinoma, squamous cell carcinoma, and carcinoma, not otherwise specified (NOS). Eligible patients were diagnosed a median of 2.5 years (range 1.0–7.2) prior to interview.

The 13 provider participants’ specialties were oncology (n = 4), emergency medicine (n = 2), cardiothoracic surgery (n = 2), gastroenterology (n = 2), internal medicine (n = 2), and obstetrics and gynecology (n = 1); the latter two specialties can be considered to provide primary care services [24].

Themes in each of the three initial time-period intervals are summarized in the text with details and supporting quotes included in corresponding tables (Tables 2, 3 and 4).

Appraisal interval

The appraisal interval encompasses the time period in which patients identify and manage their symptoms. This interval begins when patients detect bodily changes and ends when patients perceive a reason to seek care for their symptoms [27]. In this interval, we identified one barrier, minimization or misattribution of symptoms (theme 1), and one facilitator, acknowledgment of symptoms (theme 2) (Table 2).

Theme 1: minimization or misattribution of symptoms

Patients and providers described minimizing or misattributing symptoms to other causes, such as attributing a cough to allergies or asthma, or ignoring unexplained weight loss. Some patients were alarmed by their symptoms, while others were not concerned and viewed their symptoms as minor. For example, one patient described decreased energy levels and concentration that persisted for months, but this did not lead them to want to seek care. Providers noted that the non-specific nature of many symptoms associated with lung cancer can cause patients to self-manage their symptoms, as patients are likely to misattribute symptoms to less serious causes.

Theme 2: acknowledgment of symptoms

Some patients described initially ignoring symptoms until they persisted and became severe enough to affect their quality of life, including their ability to work, before actively acknowledging symptoms as a reason to seek care. Patients and providers described the role that one’s social network can play in appraising and acknowledging symptoms, such as others noticing a cough or a decrease in energy. Providers described how patient or social network appraisal of symptoms as a problem can lead to a desire to seek care.

Table 2 Themes and participant quotes in the appraisal interval

Help-seeking interval

The help-seeking interval is the time period when patients perceive a reason to seek care and ends at the first visit with a healthcare provider [27]. This interval can include the time period when a patient chooses to avoid or delay care-seeking after appraising a symptom that they feel may warrant care. In this interval we identified one barrier, hesitancy to seek care (theme 3), and one facilitator, routine care (theme 4) (Table 3).

Theme 3: hesitancy to seek care

Patients and providers both described that patients may be hesitant to seek care for various reasons, including denial or fear of being diagnosed with a serious health problem. One patient described being reluctant to contact their doctor as they were afraid that they were overreacting to their symptoms. Because many of the interviews took place during 2020 and 2021, some patients and providers also described delayed care due to fear of COVID-19 exposure.

Theme 4: routine care

Patients and providers described diagnostic workups occurring after patients mentioned a symptom during a routine care visit or seeking care for a symptom from their primary care provider. One provider described how patients who are regularly seeing a doctor are more likely to report symptoms, be referred for imaging, and receive a diagnostic work-up. Another provider explained how patients who primarily seek care from emergency departments and urgent care facilities may be less likely to have a chronic condition or malignancy diagnosed, as they do not have ongoing care from a primary care provider who has a longitudinal view of their health condition(s).

Table 3 Themes and participant quotes in the help-seeking interval

Diagnostic interval

The diagnostic interval is the time period in which a healthcare provider assesses the patient, investigates, and makes referrals to specialists. The interval begins with the first consultation with a healthcare provider and ends when the patient obtains a diagnosis [27]. In this interval, we identified two barriers, health system challenges (theme 5) and social determinants of health (theme 6), and two facilitators, severe symptoms and known risk factors (theme 7) and self-advocacy (theme 8) (Table 4). In addition to the diagnostic pathways captured by these themes, some patients had their lung cancers identified incidentally from imaging performed for reasons unrelated to lung cancer symptoms.

Theme 5: health system challenges

Patients and providers described challenges that resulted in missed opportunities for earlier diagnosis at the facility level. These challenges include managing the time it takes to schedule multiple doctor appointments when juggling a busy schedule. Systemic issues may have played a role in some diagnostic delays, as one provider described how Medicare will not cover LDCT for people who never smoked. Another provider noted that patients who present to emergency departments are more likely to get CT scans than patients seeking care from primary care providers. In addition, providers described challenges in triaging care and treating the whole body within the limited time that providers have to see patients.

Theme 6: social determinants of health

Patients and providers described how social determinants of health, including decreased access to healthcare and low socioeconomic status, can lead to a longer time to diagnosis. Patients and providers also described that living in more rural areas may present barriers to obtaining a timely diagnosis, such as limited access to medical specialists and imaging equipment causing scheduling delays and/or necessitating patient travel to access care. Providers described how patient distrust in the healthcare system that may vary by race and ethnicity can create a barrier to diagnosis. Social support, including the ability to take off work and obtain childcare that allows patients to attend healthcare appointments, can also impact the ability to receive a diagnosis in a timely manner.

Theme 7: severe symptoms and known risk factors

Patients and providers described how severe symptoms, such as hemoptysis, weight loss, shortness of breath, and chronic cough, or known risk factors, particularly smoking history, secondhand smoke exposure, or occupational exposures, can increase providers’ suspicion of lung cancer and lead to referral for imaging. Providers also described how a history of smoking influences the diagnostic work-up, as the suspicion of lung cancer is much higher in people who ever smoked than in people who never smoked.

Theme 8: self-advocacy

Patients and providers described how trusting one’s intuition regarding bodily changes, self-advocacy and persistence can lead to referrals for imaging and facilitate a diagnosis. Providers conveyed that some patients must advocate for themselves with respect to their symptoms to be referred to imaging, including one provider who described how patients sometimes must be persistent with seeking care to obtain a diagnosis.

Table 4 Themes and participant quotes in the in the diagnostic interval


This study examined barriers and facilitators to lung cancer diagnosis across the appraisal, help-seeking, and diagnostic intervals. Our study builds upon previous studies [15, 16, 19,20,21, 23] as, to our knowledge, it is the first qualitative study in the U.S. that simultaneously considered patient and provider perspectives. We report that emerging themes were similar to those identified in prior qualitative studies conducted among patients and providers outside of the U.S [15,16,17,18, 21]. and in patient-only studies conducted in the U.S [19, 26]. A key finding in this study was that themes identified between patients and providers largely aligned. Prior studies, and ours, identified barriers that may delay a diagnosis, including minimization or misattribution of symptoms, hesitancy to seek care, health system challenges, and social determinants of health. Some themes that were focused on the patient-level, such as acknowledgment of symptoms and minimization or misattribution of symptoms, may reflect system-level effects such as health literacy. The patient narratives, combined with perspectives from providers, can help to identify opportunities for interventions at the patient, provider, and health-system levels to facilitate timely diagnosis and improve patient outcomes.

The majority of lung cancers are diagnosed in unscreened individuals among both individuals who are eligible and individuals who are ineligible for screening [7]. A number of factors can contribute to delays in obtaining a lung cancer diagnosis, including typical lung cancer presentation and barriers at the individual- and system-level. While providers noted that many patients have no symptoms, they also noted that commonly described severe or alarming symptoms were hemoptysis, weight loss, shortness of breath, and chronic cough. A prior systematic review of symptomatic lung cancer diagnoses found insufficient evidence of symptoms as strong predictors of lung cancer diagnosis, apart from hemoptysis [38]. This is consistent with our study, as some patients and providers described the absence of symptoms or presentation of non-specific symptoms that can mimic or co-occur with other respiratory conditions.

It is well established that individuals who never smoked face more delays in symptom appraisal and diagnosis compared with individuals with a smoking history because they are known to have a lower risk of lung cancer [11]. We observed this in our study, as patients without a history of smoking did not consider lung cancer as a possible reason for their symptoms early on and providers described how individuals without a history of smoking are less likely to be referred for imaging, which is typically the last step in obtaining a lung cancer diagnosis. In addition, previous qualitative studies conducted in Australia [21] and New Zealand [16] observed delays at the health system-level, including delayed referral to specialists. Health system challenges, including delays and difficulty obtaining CT imaging, also emerged as a barrier in our study. Our study was also consistent with prior research reporting that lung cancer diagnosis occurs through multiple routes including routine care as well as presenting in the emergency department [23]. Previous studies have also reported the importance of social networks in appraising symptoms and advocating for care, [15, 21] consistent with patient and provider-reported themes in our study.

Strengths and limitations

Strengths of this study include our ability to examine the experiences leading up to a lung cancer diagnosis in a patient’s own words, and the fact that the patient sample was diverse in age at diagnosis, sex, cancer stage, and histotype. The majority of interviews were conducted during the height of the COVID-19 pandemic and had to be conducted over the telephone. This may have contributed to interviews being brief and may have limited the depth of responses. While we observed a repetition of themes across our data, we did not formally assess for data saturation [39]. It is possible that additional interviews could have elicited new themes related to our research question. Providers were diverse in their medical specialties, which provided a range of perspectives offering important insights as healthcare seeking patterns vary widely in the U.S. However, selection bias may be a limitation as providers with a specific interest in lung cancer may have been more motivated to participate. A limitation of this study was the lack of racial and ethnic diversity among participants, as 12 out of 13 patients identified as non-Hispanic White. As with all qualitative research, social desirability and recall biases likely influenced how participants described their experiences and perspectives. Findings from this research may not be generalizable to patients in other healthcare settings, though we believe that the themes likely resonate across populations and settings. In addition, future research is needed to determine whether pathways to lung cancer diagnosis in unscreened individuals differ between those who are eligible for asymptomatic screening and those who are ineligible.


The large proportion of lung cancers that are diagnosed among non-screened patients [6, 7] presents a need for better understanding of the pathways to diagnosis in unscreened individuals. This research identified key barriers and facilitators to lung cancer diagnosis throughout the appraisal, help-seeking, and diagnostic intervals. Minimization or misattribution of symptoms, hesitancy to seek care, access and system issues, distrust in healthcare, and rural residence continue to pose barriers to obtaining a diagnosis for some individuals. Interventions to promote patient appraisal and facilitate earlier help-seeking among individuals with symptoms may lead to faster diagnosis, particularly among individuals without a history of smoking. Potential interventions for shortening diagnosis pathways include improving patient knowledge of lung cancer symptoms and awareness of risks based on smoking history and other exposures. Patient self-advocacy for investigation of symptoms may lead to more timely imaging referral. Because X-rays have low sensitivity for lung cancer diagnosis in symptomatic individuals, it has been suggested that after negative X-ray imaging and continued symptoms, referral for CT scans should be considered by healthcare providers [40]. Further research is needed to examine how pathways to lung cancer diagnosis vary among other populations including among different racial and ethnic groups, across different healthcare and insurance systems, and across socioeconomic strata.

Fig. 1
figure 1

Model of pathways to treatment (MPT) framework used to help define the appraisal, help-seeking, and diagnostic intervals. Reproduced with permission from the publisher and authors of Scott et al., 2012 [28]

Data Availability

The interview transcripts for this study contain potentially identifiable information and are not sharable as they would compromise participant privacy and anonymity. All quotes used in analyses with extracted protected health information and identifiable information are available from the corresponding author upon reasonable request.



Models of Pathways to Treatment


United States


Low-dose computed tomography


Computed tomography


United States Preventive Services Task Force


  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

    Article  PubMed  Google Scholar 

  2. Hoffman RM, Atallah RP, Struble RD, Badgett RG. Lung Cancer screening with low-dose CT: a Meta-analysis. J Gen Intern Med. 2020;35(10):3015–25.

    Article  PubMed  PubMed Central  Google Scholar 

  3. US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962–70.

    Article  Google Scholar 

  4. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.

    Article  Google Scholar 

  5. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013;119(22):3976–83.

    Article  PubMed  Google Scholar 

  6. Fedewa SA, Kazerooni EA, Studts JL, Smith RA, Bandi P, Sauer AG, et al. State variation in low-dose computed Tomography scanning for Lung Cancer Screening in the United States. J Natl Cancer Inst. 2021;113(8):1044–52.

    Article  PubMed  Google Scholar 

  7. Olazagasti C, Ehrlich M, Kohn N, Aviles K, Hoilett A, Seetharamu N. Missed Opportunities? An observational analysis of Lung Cancer Screening utilization amongst patients with Lung Cancer. Cancer Control. 2022;29:10732748221077960.

    Article  Google Scholar 

  8. Birring SS, Peake MD. Symptoms and the early diagnosis of lung cancer. Thorax. 2005;60(4):268–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest. 1974;65(3):299–306.

    Article  CAS  PubMed  Google Scholar 

  10. Kuzniewski C, Kizhner O, Donnelly E, Henry T, Amin A, Kandathil A et al. American College of Radiology ACR Appropriateness Criteria® Chronic Cough [Internet]. 2021. Available from:

  11. van Os S, Syversen A, Whitaker KL, Quaife SL, Janes SM, Jallow M, et al. Lung cancer symptom appraisal, help-seeking and diagnosis – rapid systematic review of differences between patients with and without a smoking history. Psycho-oncology. 2022;31(4):562–76.

    Article  PubMed  Google Scholar 

  12. Wells CK, Peduzzi PN, Feinstein AR. Presenting manifestations, cigarette smoking, and Detection Bias in Age at diagnosis of Lung Cancer. Ann Epidemiol. 2001;11(4):239–47.

    Article  CAS  PubMed  Google Scholar 

  13. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, et al. Lung Cancer incidence in never smokers. JCO. 2007;25(5):472–8.

    Article  Google Scholar 

  14. Bhopal A, Peake MD, Gilligan D, Cosford P. Lung cancer in never-smokers: a hidden disease. J R Soc Med. 2019;112(7):269–71.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Christensen HM, Huniche L. Patient perspectives and experience on the diagnostic pathway of lung cancer: a qualitative study. SAGE Open Medicine. 2020;8:2050312120918996.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Walton L, McNeill R, Stevens W, Murray M, Lewis C, Aitken D, et al. Patient perceptions of barriers to the early diagnosis of lung cancer and advice for health service improvement. Fam Pract. 2013;30(4):436–44.

    Article  PubMed  Google Scholar 

  17. Corner J, Hopkinson J, Roffe L. Experience of health changes and reasons for delay in seeking care: a UK study of the months prior to the diagnosis of lung cancer. Soc Sci Med. 2006;62(6):1381–91.

    Article  PubMed  Google Scholar 

  18. Birt L, Hall N, Emery J, Banks J, Mills K, Johnson M, et al. Responding to symptoms suggestive of lung cancer: a qualitative interview study. BMJ Open Respir Res. 2014;1(1):e000067.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Carter-Harris L, Hermann CP, Draucker CB. Pathways to a lung cancer diagnosis. J Am Assoc Nurse Pract. 2015;27(10):576–83.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Carter-Harris L. Lung cancer stigma as a barrier to medical help-seeking behavior: practice implications. J Am Assoc Nurse Pract. 2015;27(5):240–5.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rankin NM, York S, Stone E, Barnes D, McGregor D, Lai M, et al. Pathways to Lung Cancer diagnosis: a qualitative study of patients and General Practitioners about diagnostic and pretreatment intervals. Annals ATS. 2017;14(5):742–53.

    Article  Google Scholar 

  22. Hall SE, Holman CDJ, Threlfall T, Sheiner H, Phillips M, Katriss P, et al. Lung cancer: an exploration of patient and general practitioner perspectives on the realities of care in rural western Australia. Aust J Rural Health. 2008;16(6):355–62.

    Article  PubMed  Google Scholar 

  23. Barrett J, Hamilton W. Pathways to the diagnosis of lung cancer in the UK: a cohort study. BMC Fam Pract. 2008;9:31.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mazzoni S, Brewer S, Durfee J, Pyrzanowski J, Barnard J, Dempsey AF, et al. Patient perspectives of Obstetrician-Gynecologists as Primary Care Providers. J Reprod Med. 2017;62(1–2):3–8.

    PubMed  Google Scholar 

  25. Levine DM, Linder JA, Landon BE. Characteristics of Americans with Primary Care and Changes over Time, 2002–2015. JAMA Intern Med. 2020;180(3):463–6.

    Article  PubMed  Google Scholar 

  26. Al Achkar M, Zigman Suchsland M, Walter FM, Neal RD, Goulart BHL, Thompson MJ. Experiences along the diagnostic pathway for patients with advanced lung cancer in the USA: a qualitative study. BMJ Open. 2021;11(4):e045056.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Walter F, Webster A, Scott S, Emery J. The Andersen Model of Total Patient Delay: a systematic review of its application in Cancer diagnosis. J Health Serv Res Policy. 2012;17(2):110–8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Scott SE, Walter FM, Webster A, Sutton S, Emery J. The model of pathways to treatment: conceptualization and integration with existing theory. Br J Health Psychol. 2013;18(1):45–65.

    Article  CAS  PubMed  Google Scholar 

  29. Blackmore T, Norman K, Kidd J, Cassim S, Chepulis L, Keenan R, et al. Barriers and facilitators to colorectal cancer diagnosis in New Zealand: a qualitative study. BMC Fam Pract. 2020;21(1):206.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Howell D, Hart R, Smith A, Macleod U, Patmore R, Roman E. Unpacking’ pathways to lymphoma and myeloma diagnosis: do experiences align with the model of pathways to treatment? Findings from a UK qualitative study with patients and relatives. BMJ Open. 2020;10(2):e034244.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Cavers D, Duff R, Bikker A, Barnett K, Kanguru L, Weller D, et al. Patient and GP experiences of pathways to diagnosis of a second primary cancer: a qualitative study. BMC Cancer. 2021;21(1):1–12.

    Article  Google Scholar 

  32. Oberoi Dv, Jiwa M, McManus A, Hodder R, de Nooijer J. Help-seeking experiences of men diagnosed with colorectal cancer: a qualitative study. Eur J Cancer Care. 2016;25(1):27–37.

    Article  CAS  Google Scholar 

  33. Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 2011;17(6):528–36.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Lawson-Michod KA, Watt MH, Grieshober L, Green SE, Karabegovic L, Derzon S, et al. Pathways to ovarian cancer diagnosis: a qualitative study. BMC Women’s Health. 2022;22(1):430.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Guest G. Applied thematic analysis. Los Angeles: Sage Publications; 2012.

    Book  Google Scholar 

  36. Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, et al. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer. 2012;106(7):1262–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Dedoose Version 9. 0.46, web application for managing, analyzing, and presenting qualitative and mixed method research data (2016). Los Angeles, CA: SocioCultural Research Consultants, LLC

  38. Shim J, Brindle L, Simon M, George S. A systematic review of symptomatic diagnosis of lung cancer. Fam Pract. 2014;31(2):137–48.

    Article  PubMed  Google Scholar 

  39. Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–907.

    Article  PubMed  Google Scholar 

  40. Bradley SH, Abraham S, Callister ME, Grice A, Hamilton WT, Lopez RR, et al. Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms: a systematic review. Br J Gen Pract. 2019;69(689):e827–35.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


We would like to thank Carlo Cardozo for his assistance with interview transcriptions.


This research was supported by the National Cancer Institute of the National Institutes of Health (P30CA042014) and in part by the Rural and Underserved Utah Training Experience at the University of Utah. Mollie E. Barnard was supported by K00CA212222 from the National Cancer Institute of the National Institutes of Health. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations



MEB, JAD, SD, SEG, LG, KLM, RDM, MO, and WLA contributed to conceptualization and study design. SEG, LK, KLM, and MO collected data. MHW guided qualitative analyses. RDM and LG conducted the qualitative analysis. LG, JAD, MHW, and RDM interpreted findings. RDM wrote the original draft. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Rachel D. McCarty.

Ethics declarations

Competing interests

Mollie E. Barnard reports personal fees from Epi Excellence LLC outside of the submitted work. All other co-authors declare no potential competing interests.

Ethics approval and consent to participate

This study was reviewed by the University of Utah Institutional Review Board and determined to be exempt (IRB #00123466). All patient participants had previously provided written informed consent for the Huntsman Cancer Institute Total Cancer Care Study. Participants received a consent cover letter by email and provided verbal consent prior to interview. All research was performed in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCarty, R.D., Barnard, M.E., Lawson-Michod, K.A. et al. Pathways to lung cancer diagnosis among individuals who did not receive lung cancer screening: a qualitative study. BMC Prim. Care 24, 203 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: